<- Go Home
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc., a gene therapy biotech company, develops treatments for rare and life-threatening genetic diseases. It offers AVXS-101, an AveXis’ gene therapy, for the treatment of spinal muscular atrophy (SMA) type 1, which is in phase 1 clinical trials. The company was formerly known as AveXis, Inc., and changed its name to Novartis Gene Therapies, Inc. in September 2020. The company was incorporated in 2010 and is based in Bannockburn, Illinois. Novartis Gene Therapies, Inc. operates as a subsidiary of Novartis AG.
Market Cap
$8.0B
Volume
453.9K
Cash and Equivalents
$586.8M
EBITDA
-$409.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$217.94
52 Week Low
$65.54
Dividend
N/A
Price / Book Value
14.08
Price / Earnings
-16.96
Price / Tangible Book Value
14.08
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$412.9M
Return on Equity
103.77%
Return on Assets
-56.43
Cash and Short Term Investments
$586.8M
Debt
N/A
Equity
$569.3M
Revenue
N/A
Unlevered FCF
-$203.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium